Triphenylbutanamines: Kinesin Spindle Protein Inhibitors with in Vivo Antitumor Activity
摘要:
The human mitotic kinesin Eg5 represents a novel mitotic spindle target for cancer chemotherapy. We previously identified S-trityl-L-cysteine (STLC) and related analogues as selective potent inhibitors of Eg5. We herein report on the development of a series of 4,4,4-triphenylbutan-1-amine inhibitors derived from the STLC scaffold. This new generation systematically improves on potency: the most potent C-trityl analogues exhibit K-i(aPP) <= 10 nM and GI(50) approximate to 50 nM, comparable to results from the phase II clinical benchmark ispinesib. Crystallographic studies reveal that they adopt the same overall binding configuration as S-trityl analogues at an allosteric site formed by loop L5 of Eg5. Evaluation of their druglike properties reveals favorable profiles for future development and, in the clinical candidate ispinesib, moderate hERG and CYP inhibition. One triphenylbutanamine analogue and ispinesib possess very good bioavailability (51% and 45%, respectively), with the former showing in vivo antitumor growth activity in nude mice xenograft studies.
Chemistry of photogenerated α-phenyl-substituted <i>o</i>-, <i>m</i>-, and <i>p</i>-quinone methides from phenol derivatives in aqueous solution
作者:Li Diao、Peter Wan
DOI:10.1139/v07-125
日期:2008.2.1
uncovered by Keith Yates as part of his now classic studies of photohydration of aromatic alkenes, alkynes, and related compounds. Photogeneration of QMs and the study of their chemistry along with potential biological applications are the focus of many groups. In this work, photochemical precursors to o-, m-, and p-QMs based on substituted phenols (hydroxybenzyl alcohols) and related compounds have
10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS
申请人:Sugimoto Tomohiro
公开号:US20110237784A1
公开(公告)日:2011-09-29
A novel 10a-azalide compound crosslinked at the 10a- and 12-positions, which is represented by the following formula, and is effective on even
Hemophilus influenzae
, or erythromycin resistant bacteria (e.g., resistant pneumococci and streptococci).
10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12
申请人:Taisho Pharmaceutical Co. Ltd.
公开号:EP2177526A1
公开(公告)日:2010-04-21
A novel 10a-azalide compound crosslinked at the 10a- and 12-positions, which is represented by the following formula, and is effective on even Hemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneumococci and streptococci).